Journal of Applied Physiology Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


J Appl Physiol 91: 1819-1827, 2001;
8750-7587/01 $5.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (25)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Komalavilas, P.
Right arrow Articles by Brophy, C. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Komalavilas, P.
Right arrow Articles by Brophy, C. M.
Vol. 91, Issue 4, 1819-1827, October 2001

PI3-kinase/Akt modulates vascular smooth muscle tone via cAMP signaling pathways

Padmini Komalavilas1, Shyamal Mehta2, Christopher J. Wingard2, Daniel T. Dransfield1, Jyoti Bhalla1, Julie E. Woodrum1, Jason R. Molinaro1, and Colleen M. Brophy3,4

1 Institute for Molecular Medicine and Genetics, 2 Department of Physiology, Medical College of Georgia, Augusta, Georgia 30912; 3 Phoenix Veterans Administration Medical Center, Phoenix 85012; and the 4 Department of Bioengineering, Arizona State University, Tempe, Arizona 85287


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Phosphatidylinositol 3-kinase (PI3-kinase) activates protein kinase B (also known as Akt), which phosphorylates and activates a cyclic nucleotide phosphodiesterase 3B. Increases in cyclic nucleotide concentrations inhibit agonist-induced contraction of vascular smooth muscle. Thus we hypothesized that the PI3-kinase/Akt pathway may regulate vascular smooth muscle tone. In unstimulated, intact bovine carotid artery smooth muscle, the basal phosphorylation of Akt was higher than that in cultured smooth muscle cells. The phosphorylation of Akt decreases in a time-dependent manner when incubated with the PI3-kinase inhibitor, LY-294002. Agonist (serotonin)-, phorbol ester (phorbol 12,13-dibutyrate; PDBu)-, and depolarization (KCl)-induced contractions of vascular smooth muscles were all inhibited in a dose-dependent fashion by LY-294002. However, LY-294002 did not inhibit serotonin- or PDBu-induced increases in myosin light chain phosphorylation or total O2 consumption, suggesting that inhibition of contraction was not mediated by reversal or inhibition of the pathways that lead to smooth muscle activation and contraction. Treatment of vascular smooth muscle with LY-294002 increased the activity of cAMP-dependent protein kinase and increased the phosphorylation of the cAMP-dependent protein kinase substrate heat shock protein 20 (HSP20). These data suggest that activation of the PI3-kinase/Akt pathway in unstimulated smooth muscle may modulate vascular smooth muscle tone (allow agonist-induced contraction) through inhibition of the cyclic nucleotide/HSP20 pathway and suggest that cyclic nucleotide-dependent inhibition of contraction is dissociated from the myosin light chain contractile regulatory pathways.

serotonin; phorbol ester; myosin light chains; cAMP-dependent protein kinase


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

THE SERINE-THREONINE KINASE Akt was identified as the product of the oncogene v-akt in the lymphomagenic murine retrovirus AKT8 (7). Because of the structural homology to protein kinase A and protein kinase C, Akt is also referred to as protein kinase B and RAC-PK (related to the A and C kinases) (11). Various growth factors activate Akt. Akt is a direct downstream target of phosphatidylinositol 3-kinase (PI3-kinase) and is involved in mediating cell survival and protection from apoptosis (17). Akt has been implicated in other biological actions such as meiosis in oocytes (1), myogenic differentiation (18), and differentiation of adipocytes (20) and several actions of insulin (29). A specific inhibitor of PI3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY-294002) (31), has been used to study the involvement of Akt in various biological functions. Wortmannin, structurally unrelated to LY-294002, also inhibits PI3-kinase (2). However, wortmannin is less specific in that it also inhibits myosin light chain kinase (MLCK) (25) and the phosphorylation of the myosin regulatory light chains [myosin light chain 20 (MLC20)] in vivo (36).

Physiological substrates of Akt include the glycogen synthase kinase 3beta (12), BAD [one of the Bcl2 family of proteins (14)], phosphofructose-2-kinase (15), and a cyclic nucleotide phosphodiesterase 3B (PDE3B) (19). Akt phosphorylates PDE3B on serine-273 in response to insulin and activates it, leading to decreases in cAMP levels in 3T3-L1 adipocytes (19). Cyclic nucleotide phosphodiesterases are a family of structurally related enzymes that hydrolyze the nucleotides cAMP and cGMP, thus inactivating the cyclic nucleotides. Phosphodiesterase 3 (PDE3) activity represents a substantial percentage of total cAMP phosphodiesterase activity in heart, blood vessels, and platelets (8). Therapeutically, the PDE3 inhibitors are used as positive inotropes, vasodilators, and inhibitors of platelet aggregation (6, 8). Molecular cloning has identified two distinct genes that encode PDE3 activity, yielding isozymes PDE3A and PDE3B. These isozymes are expressed in several tissues, including heart, aorta, liver, kidney, epididymal fat, and vascular smooth muscle (23).

cAMP and cGMP are second messengers that mediate several biological functions, including vascular smooth muscle relaxation (22, 24) and inhibition of smooth muscle contraction (38). cAMP and cGMP mediate cellular processes through activation of cAMP- and cGMP-dependent protein kinases (PKA and PKG), respectively. Because the activation of smooth muscle contraction is thought to occur through increases in intracellular Ca2+, activation of MLCK, and increases in the phosphorylation of the MLC20, many investigators have focused on mechanisms by which activation of cyclic nucleotides would lead to relaxation by reversing or inhibiting this pathway. However, the existing data suggest that cyclic nucleotide-dependent relaxation is not simply a reversal or inhibition of pathways that activate contraction (27, 38). We and others (4, 5, 27, 38) have recently determined that the small heat shock-related protein, HSP20, is a substrate of PKA and PKG that may directly mediate smooth muscle relaxation, independent of the Ca2+/MLC20 regulatory pathways. Thus we hypothesized that Akt might activate PDE3B in vascular smooth muscle maintaining low levels of cyclic nucleotides. This would facilitate agonist-induced contraction. On the other hand, inhibition of Akt would lead to increases in the levels of cyclic nucleotides, increases in the phosphorylated isoform of HSP20, and inhibition of agonist-induced contraction of vascular smooth muscle.


    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials. 12-Deoxyphorbol 13-isobutyrate (PDBu) and serotonin (5-HT) were purchased from LC Services (Woburn, MA). Forskolin and 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA)-AM were purchased from Calbiochem (La Jolla, CA), and 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY-294002) was purchased from Alexis Biochemicals (San Diego, CA). HEPES was obtained from American Bioanalytical (Natick, MA). Urea, SDS, glycine, and Tris were from Research Organics (Cleveland, OH). Coomassie brilliant blue was from ICN Biomedicals (Aurora, OH). EGTA, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS), EDTA, polyoxyethylene-sorbitan monolaurate (Tween 20), and all other reagent-grade chemicals were from Sigma Chemical (St. Louis, MO). The reagents used for electrophoretic analysis were purchased from Bio-Rad (Hercules, CA). Rabbit polyclonal anti-MLC20 antibodies were a gift from Dr. James Stull (University of Texas, Galveston, TX), and rabbit polyclonal anti-HSP20 antibodies were kindly provided by Dr. Kanefusa Kato (Aichi Human Service Center, Aichi, Japan). Anti-Akt and anti-phospho-Akt antibodies were obtained from New England Biolabs (Beverly, MA). Goat anti-rabbit secondary antibodies were from Jackson Immunochemical (West Grove, PA). Protein was estimated by the modified Bradford assay kit from Pierce (Rockford, IL).

Preparation of bovine carotid artery smooth muscle and physiological measurements. Bovine carotid arteries were dissected from fetal calves at a local abattoir (Shapiro's, Augusta, GA), placed directly in HEPES buffer (in mM: 140 NaCl, 4.7 KCl, 1.0 MgSO4, 1.0 NaH2PO4, 1.5 CaCl2, 10 glucose, and 10 HEPES; pH 7.4), and stored at 4°C for 24-72 h. The carotid vessels were dissected free from the adventitia and were opened longitudinally. The endothelium was removed by rubbing the intima with a cotton-tipped applicator. Complete denudation of endothelial cells with this technique has been previously confirmed with scanning electron microscopy (39). Transverse strips, 1.0 mm in width, were cut, and each end was tied to a loop of 3-0 silk. In some cases, rings of bovine carotid artery vessel were cut and endothelium was removed by gently denuding the intimal surface with forceps. The muscle strips were suspended in a muscle bath containing a bicarbonate buffer (in mM: 120 NaCl, 4.7 KCl, 1.0 MgSO4, 1.0 NaH2PO4, 10 glucose, 1.5 CaCl2, and 25 Na2HCO3; pH 7.4), equilibrated with 95% O2-5% CO2, at 37°C. The strips were fixed at one end to a stainless steel wire and attached to a Kent Scientific (Litchfield, CT) force transducer (TRN001) interfaced with a DT2801 analog-to-digital board (Data Translation, Marlboro, MA). Data were acquired with Dasylab software (Dasytec, Amherst, MA). For experiments in Ca2+-free conditions, the muscles were equilibrated in bicarbonate buffer without CaCl2 and containing 4 mM EGTA (an extracellular Ca2+ chelator) and 0.1 mM BAPTA-AM (an intracellular Ca2+ chelator). Depletion of extracellular Ca2+ under these conditions has been previously confirmed by failure of the muscles to contract in response to high extracellular KCl (34). All tissues were allowed to equilibrate for 1 h before the experiment. The strips were contracted with 110 mM KCl (with equimolar replacement of NaCl in bicarbonate buffer), the maximal tension obtained was taken as 100%, and tension obtained with agents (agonists, inhibitors) was determined. Force was converted to stress (105 N/m2): force (g) × 0.0987/area, where area is equal to the wet weight [mg/length (mm at maximal length)] divided by 1.055. Agonists and inhibitors were added directly to the muscle baths.

Immunoblotting for Akt and phospho-Akt. Strips of smooth muscle were treated with 50 µM LY-294002 for different time intervals and frozen in liquid N2 and pulverized. The tissue was solubilized in urea-CHAPS buffer consisting of 9 M urea, 2% CHAPS, and 100 mM dithiothreitol (DTT) followed by centrifugation (14,000 g) to remove insoluble material. Fifty micrograms of protein were resolved by SDS-PAGE using 10% polyacrylamide gels. The proteins were transferred to nitrocellulose membrane and blocked with 5% milk in Tris-buffered saline (TBS)-0.5% Tween 20. Separate blots were incubated with antibodies to Akt or phospho-Akt (1:1,000 dilution in TBS-3% bovine serum albumin) overnight at 4°C. The blots were washed with TBS-Tween 20 five times and incubated with goat anti-rabbit IgG-peroxidase secondary antibodies for 1 h at room temperature. The specific binding was detected using Supersignal chemiluminescent substrate (Pierce) and exposed to film (Kodak XAR-5). Akt and phospho-Akt bands (~59 kDa) were identified by comparisons to the markers provided in the antibody kit and were quantitated densitometrically.

Determination of myosin light chain phosphorylation. The strips of bovine carotid artery were equilibrated in a muscle bath as described above and treated with the appropriate agonists. The strips were snap frozen in dry ice-acetone, and the frozen tissue was pulverized under liquid N2. The frozen samples were placed in a frozen slurry of precipitating solution consisting of 90% acetone, 10% trichloroacetic acid, and 10 mM DTT and then allowed to melt to room temperature. The precipitating solution was removed, and the tissues were washed three times with 90% acetone and 10 mM DTT. The samples were dried, and the pellets were suspended in urea-CHAPS buffer consisting of 9 M urea, 2% CHAPS, and 100 mM DTT and then vortexed to solubilize the proteins. Ten micrograms of protein were diluted with 10 µl of urea sample buffer (6.7 M urea, 18 mM Tris, 20 mM glycine, 9 mM DTT, 4.6% saturated sucrose, and 0.004% bromophenol blue) and separated on glycerol-urea minigels (40% glycerol, 10% acrylamide, 0.5% bisacrylamide, 20 mM Tris, and 22 mM glycine) (26). Electrophoretic transfer of proteins from the gels onto nitrocellulose membranes was carried out in a buffer containing 10 mM Na2HPO4 (pH 7.6) at 25 V for 1.5 h at 20°C. The blot was blocked in 5% nonfat milk in TBS (150 mM NaCl and 10 mM Tris, pH 7.4) for 1 h and then incubated overnight at 4°C with antiserum (1:12,000 dilution in TBS with 3% bovine serum albumin) raised to bovine tracheal smooth muscle MLC20 (26). After a brief rinsing with TBS, the membrane was washed three times with buffer B (TBS containing 0.05% NP-40, 3 mM sodium deoxycholate, and 0.1% SDS), rinsed again with TBS, and incubated in goat anti-rabbit IgG-peroxidase secondary antibodies for 1 h at room temperature. The membrane was washed five times with buffer B and then rinsed with TBS before detection of bands using the Supersignal chemiluminescent substrate (Pierce).

Determination of oxygen consumption. Bovine carotid artery rings were suspended in a muscle bath containing physiological saline solution (PSS) buffer (in mM: 140 NaCl, 5.0 KCl, 1.6 CaCl2, 1.2 MgCl2, 1.2 Na2HPO4, 5.6 D-glucose, 2.0 MOPS, and 0.02 EDTA to chelate trace heavy metals; pH 7.4). The rings were contracted with either potassium PSS (109 mM, prepared by stoichiometric substitution of KCl for NaCl in PSS) or the KCl solution (PSS with a bolus addition of KCl to deliver 100 mM K+). Oxygen consumption [measured as oxygen flux (JO2)] and contractile responses were measured in bovine carotid artery rings placed in a 600-µl airtight chamber containing a Clark-style oxygen electrode (Instech Labs, Plymouth Meeting, PA) and connected to a force transducer (Grass FT03) as previously described (37). Oxygen consumption was calculated from the rate of decline in PO2 divided by the wet weight of the ring. Oxygen consumption rates were determined with a custom data collection system at a rate of five samples per second and reporting an on-line, 2-min interval, averaged JO2 every 10 s. The values are reported as means ± SE of JO2 obtained during a 2-min sampling window. Stress measurements are reported as the force generated and normalized for ring cross-sectional area at a length for optimal force generation (35).

PKA activity assay. Bovine carotid artery smooth muscle strips were treated with 100 µM LY-294002 for different time intervals and snap frozen. Strips were suspended in extraction buffer [in mM: 60 Tris · HCl (pH 7.0), 10 EGTA, 2 EDTA, 10 2-mercaptoethanol, and 0.1 NaF, protease inhibitor cocktail (Sigma Chemical) consisting of 4-(2-aminoethyl) benzenesulfonyl fluoride (AEBSF), trans-epoxysuccinyl-L-leucylamido(4-guanidino) butane (E-64), bestatin, leupeptin, aprotinin, and sodium EDTA] at a concentration of 0.5 mg/ml and then homogenized on ice using a Polytron homogenizer (Brinkman Instruments, Westbury, NY). PKA activity in the homogenates was determined using the SignaTECT PKA assay system from Promega as described by the manufacturer. PKA activity was reported as a percentage of the maximal activity in the presence of 1 mM cAMP.

HSP20 phosphorylation: isoelectric focusing immunoblots. Thirty micrograms of protein were loaded onto 12 × 15-cm slab isofocusing gels consisting of 4% acrylamide, 0.1% piperazine diacrylamide, 9 M urea, 5% ampholines (5 parts 6-8, 3 parts 5-7, and 2 parts 3-10), and 2% CHAPS. The cathode buffer consisted of 20 mM sodium hydroxide, and the anode buffer consisted of 10 mM phosphoric acid. The proteins were focused for 10,000 V · h. The gels were equilibrated in 10 mM Tris (pH 6.8), 3% SDS, 19% ethanol, 4% 2-mercaptoethanol and 0.004% bromophenol blue for 30 min. The gels were then transferred to Immobilon (100 mA) for 12 h. The blots were fixed with 20% methanol, dried, blocked with TBS (10 mM Tris, 150 mM NaCl, and 0.5% Tween 20, pH 7.4) and 5% milk for 1 h, washed three times with TBS, and then probed with anti-HSP20 antibodies (1:1,000 dilution in TBS, 5% milk) for 1 h. The blots were washed six times with TBS, 0.5% Tween 20, and incubated with goat anti-rabbit IgG-peroxidase secondary antibodies for 1 h at room temperature. The specific binding was detected using Supersignal chemiluminescent substrate (Pierce) and exposed to film, and the bands were quantitated densitometrically.

Statistical analysis. Data are presented as means ± SE. Statistical analysis was performed by unpaired Student's t-test or one-way ANOVA followed by Newman-Keul's test for comparing two mean values and multiple means, respectively, with a P value of <0.05 considered significant. Densitometric analysis was performed using Desk Scan II and the software Un-scan-it gel (Silk Scientific). The phosphorylated and nonphosphorylated HSP20 and MLC20 bands were quantitated densitometrically. The relative amounts of the phosphorylated forms of HSP20 and MLC20 over the total amount of HSP20 and MLC20 were calculated and reported.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Phosphorylation of Akt in vascular smooth muscle. Because Akt is a downstream substrate of PI3-kinase (10), we examined the effect of PI3-kinase inhibition by LY-294002 on the phosphorylation state of Akt. Bovine carotid artery strips were incubated with LY-294002 (50 µM) for different time intervals, and the phosphorylation state of Akt was analyzed using a phosphorylation state-specific Akt antibody. Basal phosphorylation of Akt was reduced in a time-dependent manner on incubation with LY-294002 (Fig. 1, A and B). Basal phosphorylation of Akt in intact bovine carotid artery smooth muscle was higher than the phosphorylation observed in cultured vascular smooth muscle cells (8.1 ± 1.52-fold compared with mesangial cells and 4.1 ± 0.27-fold compared with rat aortic smooth muscle cells, respectively, Fig. 1C). 5-HT stimulation (1 µM for 10 min) did not lead to significant increases in the phosphorylation of Akt in bovine carotid artery smooth muscle (data not shown). It has been demonstrated earlier that 5-HT does not increase Akt phosphorylation in rat aortic smooth muscle cells, whereas LY-294002 abolished epidermal growth factor-stimulated Akt phosphorylation (3)


View larger version (33K):
[in this window]
[in a new window]
 
Fig. 1.   Inhibition of phosphorylation of Akt (also known as PKB) by LY-294002 in bovine carotid artery. Bovine carotid artery smooth muscle strips were prepared as described in EXPERIMENTAL PROCEDURES and equilibrated in bicarbonate buffer in a conical tube and aerated with 95% O2-5% CO2 at 37°C for 1 h. The strips were incubated with LY-294002 (50 µM) for different time intervals and snap frozen in liquid N2. Fifty micrograms of protein were analyzed by SDS-PAGE and transferred to nitrocellulose membrane and probed with anti-Akt or anti-phospho-Akt antibodies. A: immunoblot showing phosphorylation of Akt (p-Akt) at ~59 kDa and expression of total Akt protein (Akt) at ~59 kDa. B: averaged densitometric data (means ± SE for 3 independent experiments). Data were quantified by densitometry of immunoblots and expressed as percent phosphorylation of Akt, in which the phosphorylation of control muscle strips with no LY-294002 added is defined as 100%. *P < 0.05, compared with basal phosphorylation of Akt in control strips in the absence of LY-294002. C: basal phosphorylation of Akt in mesangial cells (MC), rat aortic smooth muscle cells (RASC), and bovine carotid artery smooth muscle (BCA). Fifty micrograms of proteins were separated on 10% SDS-PAGE and probed using either phosphospecific Akt or Akt antibodies, and the bands were quantitated densitometrically. Data are represented as densitometric units (means ± SE for 3 independent experiments). *P < 0.05, compared with basal phosphorylation of Akt in mesangial cells and rat aortic smooth muscle cells.

Inhibition of smooth muscle contraction by LY-294002. Treatment of bovine carotid artery smooth muscle with 5-HT (1 µM) led to a rapid, sustained contraction (109.14 ± 5.39% of the active stress KCl response, n = 4; Fig. 2A). Pretreatment of the muscle strip with LY-294002 (50 µM, 30 min) before 5-HT significantly inhibited the magnitude of contraction (4.52 ± 3.41% KCl response; Fig. 2A) in a dose-dependent fashion (Fig. 2, B and C). Addition of LY-294002 (30 µM) followed by 5-HT (1 µM) also significantly inhibited contraction (25.3 ± 2.40% and 22.4 ± 1.90% KCl response at 15 and 30 min, respectively; data not shown). The effect of LY-294002 was reversible in that the muscle strips contracted to 5-HT (99.08 ± 6.31% KCl response) after washout and equilibration for 2 h (data not shown).


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 2.   Inhibition of serotonin (5-HT)-induced contraction by LY-294002 in bovine carotid artery. Bovine carotid artery smooth muscle strips were prepared as described in EXPERIMENTAL PROCEDURES and equilibrated in bicarbonate buffer in a muscle bath for 1 h. Muscle strips were then treated with 110 mM KCl (K+), and tension was recorded. Muscle strips were washed 3 times (wash) and equilibrated in bicarbonate buffer for 30 min and then with LY-294002 (0, 3, 10, 30, or 100 µM) for 30 min followed by 1 µM 5-HT, and the force generated was recorded and converted to stress. A: representative tracing of high KCl contraction (KCl) followed by 5-HT (1 µM) and then with LY-294002 (50 µM) for 30 min followed by 5 HT (1 µM). B: representative tracings of force generated when muscle strips were incubated with 0 (a), 3 (b), 10 (c), 30 (d), or 100 (e) µM LY-294002 for 30 min followed by 5-HT (1 µM). C: averaged data (means ± SE for 3 independent experiments), expressed as relative stress with respect to KCl response in which stress value obtained with KCl was defined as 100%. *P < 0.05.

Phorbol esters, which activate protein kinase C, elicit contraction of smooth muscle even under circumstances where intracellular Ca2+ levels are low or fixed (13, 30, 34). Thus, to determine whether the effect of inhibition of PI3-kinase was related to agonist (5-HT)-induced increases in Ca2+ (21), we examined the effect of LY-294002 on PDBu-elicited contractions in the absence of Ca2+ using intra- and extracellular Ca2+ chelators. PDBu treatment elicited a slowly developing contraction (Fig. 3A) under Ca2+-free conditions that reached a steady state by 30 min (42.05 ± 8.16% KCl response; n = 6). These contractions were also inhibited by LY-294002 in a dose-dependent manner (Fig. 3, B and C). In the presence of Ca2+, PDBu also elicited a strong contraction (69.02 ± 3.57% KCl response) that was inhibited (6.26 ± 2.05% KCl response) by LY-294002 (Fig. 5C).


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 3.   Inhibition of 12-deoxyphorbol 13-isobutyrate (PDBu)-induced contraction by LY-294002 in bovine carotid artery. Bovine carotid artery smooth muscle strips were prepared as described in EXPERIMENTAL PROCEDURES and equilibrated in bicarbonate buffer in a muscle bath for 1 h. Muscle strips were then treated with 110 mM KCl (K+, stoichiometric substitution of KCl for NaCl in the bicarbonate buffer), and tension was recorded and converted to stress. Muscle strips were washed three times (wash) and equilibrated with bicarbonate buffer without CaCl2, containing 4 mM EGTA and 0.1 mM BAPTA-AM (extracellular and intracellular Ca2+ chelator, respectively) for an additional 1 h. Depletion of Ca2+ was confirmed by stimulation of the muscle strips with 5-HT (1 µM). Muscle strips were then treated with LY-294002 (0, 10, 30, or 100 µM) for 30 min followed by PDBu (0.7 µM), and tension was recorded at different time intervals. A: representative tracing showing the stress values for KCl and PDBu (0.7 µM). B: representative tracings of stress values when muscle strips in Ca2+-free conditions were incubated with 0 (a), 10 (b), 30 (c), or 100 (d) µM LY-294002 for 30 min followed by 0.7 µM PDBu. C: averaged data (means ± SE for 3 independent experiments), expressed as relative stress with respect to KCl response in which stress obtained with KCl was defined as 100%. *P < 0.05, compared with force generated in the absence of LY-294002.

Smooth muscle contraction can also be elicited by depolarization of the membrane with high extracellular KCl that leads to an influx of Ca2+. KCl-induced contraction was inhibited in a dose-dependent manner by LY-294002 (Fig. 4, A and B). However, although LY-294002 (100 µM) completely inhibited 5-HT- or PDBu-induced contractions, KCl contractions were only inhibited by 50%.


View larger version (13K):
[in this window]
[in a new window]
 
Fig. 4.   Inhibition of KCl contraction by LY-294002. Bovine carotid rings were prepared as described in EXPERIMENTAL PROCEDURES and equilibrated in MOPS-based buffer (physiological saline solution) for 1 h. A: mean active stress response of bovine carotid artery rings to K+-physiological saline solution (Na+ substitution) and 100 mM KCl (bolus addition) before and after 30-min preincubation of graded concentrations of LY-294002 (3-100 µM). Reported are mean active stresses of 4 different arteries. Standard errors are not reported for clarity. B: dose-response curve for the impact of preincubation of LY-294002 (3-100 µM) on KCl-induced active stress generation. Reported are means ± SE of 4 arteries. *P < 0.05 compared with relative KCl response in which active stress obtained with KCl was defined as 100%.

Effect of PI3-kinase inhibition on MLC20 phosphorylation. Because the activation of vascular smooth muscle contraction is associated with increases in intracellular Ca2+, activation of MLCK, and increases in the phosphorylation of the regulatory MLC20, we conducted experiments to determine whether inhibition of PI3-kinase led to changes in MLC20 phosphorylation. Stimulation of smooth muscle strips with 5-HT (1 µM for 2 min) led to increases in MLC20 phosphorylation (0.50 ± 0.05 mol Pi/mol MLC20; Fig. 5, A and B). However, preincubation of the smooth muscle strips with LY-294002 (50 µM, 30 min) before stimulation with 5-HT did not significantly inhibit (0.51 ± 0.03 mol Pi/mol MLC20) the MLC20 phosphorylation (Fig. 5, A and B). Thus 5-HT-induced contractile force was inhibited by LY-294002, but MLC20 phosphorylation was not (Fig. 5C). Similarly, PDBu stimulation induced significant MLC20 phosphorylation to 0.26 ± 0.03 and 0.27 ± 0.03 mol Pi/mol MLC20 in the presence and absence of LY-294002, respectively (Fig. 5, A and B).


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 5.   Contraction and myosin light chain phosphorylation in the presence of LY-294002, 5-HT, and 12-deoxyphorbol 13-isobutyrate. Bovine carotid artery smooth muscle strips were prepared as described in EXPERIMENTAL PROCEDURES and equilibrated in bicarbonate buffer in a muscle bath for 1 h. Muscle strips were then treated with 110 mM KCl, and tension was recorded. Muscle strips were washed 3 times, equilibrated in bicarbonate buffer for 30 min, and then stimulated with 5-HT (1 µM), PDBu (0.7 µM), LY-294002 (LY294; 50 µM) for 30 min followed by 5-HT or PDBu, or 50 µM LY-294002. The muscle strips were snap frozen after 2 (5-HT) or 40 (PDBu) min, and myosin light chain 20 (MLC20) phosphorylation was determined as described in EXPERIMENTAL PROCEDURES. A: representative immunoblot of the urea-glycerol gel with MLC20 and phosphorylated (P) MLC20. B: quantitation of the densitometric analysis of the immunoblot, expressed as mol Pi/mol MLC20. *P < 0.05 (n = 3), compared with the respective basal phosphorylation. C: averaged data (means ± SE; n = 3-5) for contraction measurement during stimulation of the muscle strips with the agonists expressed as relative stress with respect to KCl response in which stress obtained with KCl was defined as 100%. *P < 0.05, compared with contraction in the absence of LY-294002.

Effect of PI3-kinase inhibition on oxygen consumption. Due to the relatively slow time course of smooth muscle contraction and the limited phosphocreatine and glycogen stores, there is a tight association between increased energy utilization and metabolic recovery (16). One of the more unique properties of smooth muscle is an energetic behavior that is well correlated with the extent of myosin light chain phosphorylation (28). We studied the energetic state of the carotid artery, oxygen consumption, and the stress in carotid artery rings stimulated with 5-HT in the absence and presence of LY-294002. The magnitude of the JO2 increase with 5-HT stimulation was similar in the presence (25.7 ± 8.6 nmol O2 · min-1 · g-1) or absence of the LY-294002 (26.4 ± 9.1 nmol O2 · min-1 · g-1), suggesting an equivalent total energetic cost for 5-HT activation of this tissue.

Activation of PKA by LY-294002. One reported substrate of Akt is PDE3 (19). To determine whether the inhibition of PI3-kinase inhibited smooth muscle contraction by increases in cyclic nucleotide levels, we measured the activity of PKA in the presence and absence of LY-294002 (100 µM). PKA activity was significantly increased in smooth muscle strips treated with LY-294002 (Fig. 6).


View larger version (12K):
[in this window]
[in a new window]
 
Fig. 6.   LY-294002 increases cAMP-dependent protein kinase (PKA) activity in bovine carotid artery smooth muscle. Bovine carotid artery smooth muscle strips were treated with either DMSO (control) or LY-294002 (100 µM, indicated times), and PKA activity was determined as described in EXPERIMENTAL PROCEDURES. Reported are means ± SE with n = 5. *P < 0.05, compared with control untreated tissues.

HSP20 phosphorylation. Both relaxation and inhibition of contraction of carotid artery smooth muscle is associated with increases in the phosphorylation of the small heat shock-related protein, HSP20 (5, 27, 38). HSP20 is also phosphorylated in response to insulin and insulin antagonists in rat skeletal and smooth muscle (32, 33). Because treatment of carotid artery smooth muscle with LY-294002 leads to activation of PKA and PKA phosphorylates HSP20, we examined HSP20 phosphorylation in response to LY-294002. Treatment with LY-294002 led to significant increases in the phosphorylation of HSP20. These increases were comparable to those seen after treatment with the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine (1 mM) and the PKA activator forskolin (10 µM; Fig. 7).


View larger version (11K):
[in this window]
[in a new window]
 
Fig. 7.   LY-294002 induces phosphorylation of the small heat shock protein HSP20 in bovine carotid artery smooth muscle. Bovine carotid artery smooth muscle strips were prepared as described earlier and equilibrated in bicarbonate buffer in a conical tube and aerated with 95% O2-5% CO2 at 37°C for 1 h. The strips were incubated with no agents (control, cont), 3-isobutyl-1-methylxanthine (IBMX, 1 mM) + forskolin (FSK, 10 µM) for 10 min, or different concentrations (10 and 100 µM) of LY-294002 for 30 min and snap frozen in liquid N2. Thirty micrograms of protein were analyzed by isoelectric focusing as described in EXPERIMENTAL PROCEDURES and transferred to Immobilon membrane and probed with anti-HSP20 antibodies. Averaged densitometric data, expressed as percent of phosphorylated form of HSP20 (means ± SE for 3 independent experiments), were quantified by densitometry of immunoblots, and relative amounts of phosphorylated HSP20 over the total HSP20 were calculated. *P < 0.05, compared with basal phosphorylation of HSP20 in control muscle strips.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

In this study, we observed that there was a significant level of basal phosphorylation of Akt in intact vascular smooth muscles compared with cultured vascular smooth muscle cells (Fig. 1), suggesting a high basal activity of PI3-kinase in intact vascular smooth muscle. Results from this study demonstrated that inhibition of this basal activity by the PI3-kinase inhibitor LY-294002 inhibited the ability of bovine carotid artery smooth muscle to contract in response to various contractile stimuli, even though the stimuli did not involve activation of PI3-kinase. Consequently, we designed experiments to study the effect of LY-294002 on the basal activity of the downstream substrate of PI3-kinase, Akt, and subsequent changes in signaling events downstream of Akt activation.

The basal level of phosphorylation of Akt was inhibited by the PI3-kinase inhibitor, LY-294002 (Fig. 1; Ref. 31). Recently, Akt was determined to activate a phosphodiesterase (19), leading to a decrease in intracellular cyclic nucleotide levels. Because increases in intracellular cyclic nucleotides inhibit contraction of vascular smooth muscle, we examined the effect of LY-294002 on physiological contractile responses and the activation of contractile signaling pathways. Treatment of intact vascular smooth muscles with LY-294002 inhibited agonist (5-HT)-, phorbol ester (PDBu)-, and depolarization (KCl)-induced contractions in a dose-dependent manner (Figs. 2-4). LY-294002 had a maximal effect on 5-HT- and PDBu-induced contractions and partial effects on KCl-induced contractions. This differential effect could be partially explained by the fact that these agents initiate contraction by different mechanisms and depolarization-induced contraction is blocked by cyclic nucleotides less effectively than agonist-induced contraction. 5-HT causes vascular smooth muscle contraction by interacting with cell surface receptors and activating signaling pathways that lead to increases in intracellular Ca2+ and activation of protein kinase C (21). Banes et al. (3) reported that LY-294002 inhibits 5-HT-induced contraction in rat aorta. However, they attributed the inhibition of contraction to the possibility of LY-294002 being a 5-HT2A receptor antagonist. Phorbol esters do not require receptor activation and directly activate protein kinase C. We determined that LY-294002 inhibits contractions elicited by the phorbol ester PDBu. Most investigators have focused on the role of the Ca2+, MLCK, and regulatory myosin light chain phosphorylation pathway of muscle contraction. Interestingly, LY-294002 inhibited contractions induced by depolarization with high K+, which leads to increases in intracellular Ca2+. In addition, LY-294002 also inhibited phorbol ester-induced contractions under conditions in which intra- and extracellular Ca2+ is chelated. Taken together, these data suggest that LY-294002 is inhibiting muscle contraction by activating pathways independent of increases in intracellular Ca2+ and myosin light chain phosphorylation.

To directly determine the effect of LY-294002 on the MLC20/MLCK pathway, we measured the phosphorylation of the regulatory myosin light chains. Increases in MLC20 phosphorylation were similar in response to 5-HT and PDBu in the presence and absence of LY-294002 (Fig. 5). Thus there were similar increases in MLC20 phosphorylation under conditions in which stress was present (agonist alone) and absent (LY-294002 before agonist). Finally, we examined the energetic response of the bovine carotid smooth muscle during 5-HT stimulation in the presence and absence of LY-294002. The JO2 served as an indirect measure of the activation state of the tissue reflecting a combination of cross-bridge ATPase activity and the oxidative energy necessary to activate the tissue (e.g., regulatory myosin light chain phosphorylation/dephosphorylation) (37). This suggests that the energetic consequences of 5-HT stimulation are equivalent in both the presence and absence of LY-294002. When viewed with the myosin light chain phosphorylation measurements, we postulate that the impaired force generation ability seen in the presence of LY-294002 relies on a mechanism that does not impair the tissue activation pathway that utilizes light chain phosphorylation and thus cross-bridge cycling. Because energy demands for cross-bridge ATPase activity and myosin light chain phosphorylation can be nearly equivalent at high levels of phosphorylation (37), the substantial energetic cost seen here could account for the moderate levels of phosphorylation. This would be expected if the proposed relaxation mechanism were working by a process independent of myosin phosphorylation and cross-bridge cycling.

To determine whether inhibition of the PI3-kinase/Akt pathway in vascular smooth muscle inhibits contractile responses through the cyclic nucleotide-dependent signaling pathway, we measured the activity of PKA. Treatment of vascular smooth muscle with LY-294002 increased PKA activity (Fig. 6). Because the only known activators of PKA are cyclic nucleotides, this provides indirect evidence that inhibition of PI3-kinase leads to increases in intracellular cyclic nucleotide concentrations. It is likely that the increase in basal concentration of cyclic nucleotides in response to LY-294002 also leads to activation of PKG, since cross-activation of PKG by cAMP during vascular smooth muscle relaxation is possible and has been demonstrated previously by several investigators (22). The specific mechanisms by which activation of cyclic nucleotide-dependent protein kinases leads to vasorelaxation and inhibition of contraction are not known. However, recent attention has been focused on HSP20. HSP20 is phosphorylated in vascular smooth muscle in response to activation of cyclic nucleotide-dependent signaling pathways (5). In addition, HSP20 is not phosphorylated in a muscle that is uniquely refractory to cyclic nucleotide-dependent relaxation, the human umbilical smooth muscle (9). HSP20 can be phosphorylated in vitro by both PKA and PKG (5). The physiologically relevant site of phosphorylation on HSP20 appears to be serine-16 (4). Transient permeabilization of vascular smooth muscle and the introduction of phosphopeptide analogs of HSP20 inhibit agonist-induced contractions of the muscles (4). In this study, we demonstrate that inhibition of PI3-kinase with LY-294002 also leads to increases in the phosphorylation of the PKA substrate HSP20 (Fig. 7).

Taken together, these data suggest that the basal activity of PI3-kinase is necessary for contraction of vascular smooth muscle by contractile agents. The physiological consequences of this pathway appear to be the lowering of intracellular cyclic nucleotide levels to allow agonist-induced contraction to occur (Fig. 8). Finally, the results of this study suggest that inhibition of the basal activation of PI3-kinase/Akt pathway leads to activation of the cyclic nucleotide-dependent signaling pathway with subsequent increases in the phosphorylation of HSP20. The cyclic nucleotide pathway inhibits agonist-induced contraction in a manner that is dissociated from the MLCK/MLC20 pathway in that force generation is inhibited but myosin light chain phosphorylation and energy consumption are not. Although the mechanisms by which phosphorylated HSP20 inhibits the generation of force are not known, it is interesting to speculate that HSP20 may be directly interacting with specific, but as yet not defined, elements of the contractile machinery. Because PDE3 inhibitors are used as positive inotropes, vasodilators, and inhibitors of platelet aggregation, manipulation of PDE activity and cAMP levels through this pathway may have therapeutic potential in the treatment of vasospastic disorders.


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 8.   Schematic representation of the regulation of vascular smooth muscle tone by phosphatidylinositol 3-kinase (PI3-K; PI3-kinase)/Akt. PI3-kinase activates Akt, which phosphorylates PDE3 leading to its activation. PDE3 degrades cAMP lowering the intracellular concentration of cAMP, enabling contraction by agonists KCl and phorbol ester. When PI3-kinase is blocked with LY-294002, Akt is inactivated, leading to inactivation of PDE3 and accumulation of cAMP levels. This activates PKA, which phosphorylates HSP20 and phosphorylated HSP20 inhibits contraction by an unknown mechanism. IP3, inositol trisphosphate; DAG, diacylglycerol; ?, possibly.


    ACKNOWLEDGEMENTS

We thank Drs. James Stull and Kanefusa Kato for generously supplying antibodies, Dr. Kristine Kamm for the advice on myosin light chain phosphorylation, and Shapiro's Meatpackers for bovine carotid arteries.


    FOOTNOTES

This work was supported by a Veterans Affairs Merit Review Award and National Heart, Lung, and Blood Institute Grant RO1 HL-58027-01 (to C. M. Brophy) and by American Heart Association, Southest Affiliate, and National Heart Foundation Awards (to C. J. Wingard).

Address for reprint requests and other correspondence: C. M. Brophy, Phoenix VAMC, 650 E. Indian School Rd. CS112, Phoenix, AZ 85012 (E-mail: colleen.brophy{at}med.va.gov).

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 23 March 2001; accepted in final form 22 June 2001.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1.   Anderson, CB, Roth RA, and Conti M. Protein kinase B/Akt induces resumption of meiosis in Xenopus oocytes. J Biol Chem 273: 18705-18708, 1998[Abstract/Free Full Text].

2.   Arcaro, A, and Wyman MP. Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: the role of phosphatidylinositol 3,4,5 trisphosphate in neutrophil responses. Biochem J 296: 297-301, 1993.

3.   Banes, A, Florian JA, and Watts SW. Mechanisms of 5-hydroxytryptamine2A receptor activation of the mitogen-activated protein kinase pathway in vascular smooth muscle. J Pharmacol Exp Ther 291: 1179-1187, 1999[Abstract/Free Full Text].

4.   Beall, A, Bagwell D, Woodrum DA, Stoming TA, Kato K, Suzuki A, Rasmussen H, and Brophy CM. The small heat shock-related protein, HSP20, is phosphorylated on serine 16 during cyclic nucleotide-dependent relaxation. J Biol Chem 274: 11344-11351, 1999[Abstract/Free Full Text].

5.   Beall, AC, Kato K, Goldenring JR, Rasmussen H, and Brophy CM. Cyclic nucleotide-dependent vasorelaxation is associated with the phosphorylation of a small heat shock-related protein. J Biol Chem 272: 11283-11287, 1997[Abstract/Free Full Text].

6.   Beavo, JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 75: 725-748, 1995[Abstract/Free Full Text].

7.   Bellacosa, A, Testa JR, Staal SP, and Tsichlis PN. A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. Science 254: 274-277, 1991[Abstract/Free Full Text].

8.   Bolger, G, Michaeli T, Martins T, St. John T., Steiner B, Rodgers L, Riggs M, Wigler M, and Ferguson K. A family of human phosphodiesterases homologues to the dunce learning and memory gene product of Drosophila melanogaster are potential targets for antidepressant drugs. Mol Cell Biol 13: 6558-6571, 1993[Abstract/Free Full Text].

9.   Brophy, CM, Beall A, Lamb S, Dickinson M, and Ware DJ. Small heat shock proteins and vasospasm in human umbilical artery smooth muscle. Biol Reprod 57: 1354-1359, 1997[Abstract].

10.   Coffer, PJ, Jin J, and Woodgett JR. Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation. Biochem J 335: 1-13, 1998.

11.   Coffer, PJ, and Woodgett JR. Molecular cloning and characterisation of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families. Eur J Biochem 201: 475-481, 1991[Web of Science][Medline].

12.   Cross, DAE, Alessi DR, Cohen P, Andjelkovich M, and Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378: 785-789, 1995[Medline].

13.   Danthuluri, NR, and Deth RC. Phorbol ester induced contraction of arterial smooth muscle and inhibition of alpha -adrenergic response. Biochem Biophys Res Commun 125: 1103-1109, 1984[Web of Science][Medline].

14.   Datta, SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, and Greenberg ME. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91: 231-241, 1997[Web of Science][Medline].

15.   Deprez, J, Vertommen D, Alessi DR, Hue L, and Rider MK. Phosphorylation and activation of heart 6-phosphofructo-2-kinase by protein kinase B and other protein kinases of the insulin signaling cascades. J Biol Chem 272: 17269-17275, 1997[Abstract/Free Full Text].

16.   Hellstrand, P. Energetics of smooth muscle contraction. In: Biochemistry of Smooth Muscle Contraction, edited by Barany M.. San Diego, CA: Academic, 1996, p. 379-392.

17.   Hemmings, BA. Akt signaling: linking membrane events to life and death decisions. Science 275: 628-630, 1997[Free Full Text].

18.   Jiang, B-H, Aoki M, Zheng JZ, Li Z, and Vogt PK. Myogenic signaling of phosphatidylinositol 3-kinase requires the serine-threonine kinase Akt/protein kinase B. Proc Natl Acad Sci USA 96: 2077-2081, 1999[Abstract/Free Full Text].

19.   Kitamura, T, Kitamura Y, Kudora S, Hino Y, Ando M, Kotani K, Konishi H, Matsuzaki H, Kikkawa U, Ogawa W, and Kasuga M. Insulin-induced phosphorylation and activation of cyclic nucleotide phosphodiesterase 3B by the serine-threonine kinase Akt. Mol Cell Biol 19: 6286-6296, 1999[Abstract/Free Full Text].

20.   Kohn, AD, Summers SA, Birnbaum MJ, and Roth RA. Expression of constitutively active Akt Ser/Thr kinase in 3T3-L1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation. J Biol Chem 271: 31372-31378, 1996[Abstract/Free Full Text].

21.   Kotlikoff, MI, Herrera G, and Nelson MT. Regulation of cytosolic-calcium in smooth muscle. In: Reviews of Physiology Biochemistry and Pharmacology, edited by Murphy RA.. Berlin: Springer-Verlag, 1999, p. 147-201.

22.   Lincoln, TM. Cyclic GMP: Biochemistry, Physiology and Pathophysiology. Austin, TX: Landes, 1994.

23.   Liu, H, and Maurice DH. Expression of cyclic GMP-inhibited phosphodiesterase 3A and 3B (PDE3A and PDE3B) in rat tissues: differential subcellular localization and regulated expression by cyclic AMP. Br J Pharmacol 125: 1501-1510, 1998[Web of Science][Medline].

24.   Murray, KJ. Cyclic AMP and mechanisms of vasodilation. Pharmacol Ther 47: 329-345, 1990[Web of Science][Medline].

25.   Nakanishi, S, Kakita S, Takahashi I, Kawahara K, Tsukuda E, Sano T, Yamada K, Yoshida M, Kase H, and Matsuda Y. Wortmannin, a microbial product inhibitor of myosin light chain kinase. J Biol Chem 267: 2157-2163, 1992[Abstract/Free Full Text].

26.   Persechini, A, Kamm KE, and Stull JT. Different phosphorylated forms of myosin in contracting tracheal smooth muscle. J Biol Chem 261: 6293-6299, 1986[Abstract/Free Full Text].

27.   Rembold, CM, Foster DB, Strauss JD, Wingard CJ, and Van Eyk JE. cGMP-mediated phosphorylation of heat shock protein 20 may cause smooth muscle relaxation without myosin light chain dephosphorylation in swine carotid artery. J Physiol (Lond) 524: 865-878, 2000[Abstract/Free Full Text].

28.   Strauss, JD, and Murphy RA. Regulation of cross-bridge cycling in smooth muscle. In: Biochemistry of Smooth Muscle Contraction, edited by Barany M.. San Diego, CA: Academic, 1996, p. 341-353.

29.   Takata, M, Ogawa W, Kitamura T, Hino Y, Kuroda S, Kotani K, Klip A, Gingras AC, Sonenberg N, and Kasuga M. Requirement for Akt (protein kinase B) in insulin-induced activation of glycogen synthase and phosphorylation of 4E-BP (PHAS-1). J Biol Chem 274: 20611-20618, 1999[Abstract/Free Full Text].

30.   Throckmorton, DC, Packer CS, and Brophy CM. Protein kinase C activation during Ca2+-independent vascular smooth muscle contraction. J Surg Res 78: 48-53, 1998[Web of Science][Medline].

31.   Vlahos, CJ, Matter WF, Hui KY, and Brown RF. Specific inhibitor of phosphatidylinositol 3-kinase, 2-morpholinyl -8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 269: 5241-5248, 1994[Abstract/Free Full Text].

32.   Wang, Y, Xu A, and Cooper GJS Phosphorylation of P20 is associated with the actions of insulin in rat skeletal and smooth muscle. Biochem J 344: 971-976, 1999.

33.   Wang, Y, Xu A, Pearson RB, and Cooper GJS Insulin and insulin antagonists evoke phosphorylation of P20 at serine 157 and serine 16 respectively in rat skeletal muscle. FEBS Lett 462: 25-30, 1999[Web of Science][Medline].

34.   Whitney, G, Throckmorton DC, Isales C, Takuwa Y, Yeh J, Rasmussen H, and Brophy CM. Kinase activation and smooth muscle contraction in the presence and absence of calcium. J Vasc Surg 22: 37-44, 1995[Web of Science][Medline].

35.   Wingard, CJ, Browne AK, and Murphy RA. Dependence of force on length at constant cross-bridge phosphorylation in the swine carotid media. J Physiol (Lond) 488: 729-739, 1995[Abstract/Free Full Text].

36.   Wingard, CJ, and Murphy RA. Inhibition of Ca2+ -dependent contraction in swine carotid artery by myosin kinase inhibitors. Gen Pharmacol 32: 483-494, 1999[Web of Science][Medline].

37.   Wingard, CJ, Paul RJ, and Murphy RA. Energetic cost of activation processes during contraction of swine arterial smooth muscle. J Physiol (Lond) 501: 213-223, 1997[Abstract/Free Full Text].

38.   Woodrum, DA, Brophy CM, Wingard CJ, Beall A, and Rasmussen H. Phosphorylation events associated with cyclic nucleotide-dependent inhibition of smooth muscle contraction. Am J Physiol Heart Circ Physiol 277: H931-H939, 1999[Abstract/Free Full Text].

39.   Yeh, JL, Whitney EG, Lamb S, and Brophy CM. Nitric oxide is an autocrine feedback inhibitor of vascular smooth muscle contraction. Surgery 119: 104-109, 1996[Web of Science][Medline].


J APPL PHYSIOL 91(4):1819-1827



This article has been cited by other articles:


Home page
Reproductive SciencesHome page
Y. Cordeaux, H. Missfelder-Lobos, D. S. Charnock-Jones, and G. C. S. Smith
Stimulation of Contractions in Human Myometrium by Serotonin is Unmasked by Smooth Muscle Relaxants
Reproductive Sciences, September 1, 2008; 15(7): 727 - 734.
[Abstract] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
H. El-Haroun, D. L. Clarke, K. Deacon, D. Bradbury, A. Clayton, A. Sutcliffe, and A. J. Knox
IL-1{beta}, BK, and TGF-{beta}1 attenuate PGI2-mediated cAMP formation in human pulmonary artery smooth muscle cells by multiple mechanisms involving p38 MAP kinase and PKA
Am J Physiol Lung Cell Mol Physiol, March 1, 2008; 294(3): L553 - L562.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
A. S. Braverman, A. S. Tibb, and M. R. Ruggieri Sr
M2 and M3 Muscarinic Receptor Activation of Urinary Bladder Contractile Signal Transduction. I. Normal Rat Bladder
J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 869 - 874.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
U. K. Misra and S. V. Pizzo
Coordinate Regulation of Forskolin-induced Cellular Proliferation in Macrophages by Protein Kinase A/cAMP-response Element-binding Protein (CREB) and Epac1-Rap1 Signaling: EFFECTS OF SILENCING CREB GENE EXPRESSION ON Akt ACTIVATION
J. Biol. Chem., November 18, 2005; 280(46): 38276 - 38289.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
S. L. Jones and Y. Sharief
Asymmetrical protein kinase A activity establishes neutrophil cytoskeletal polarity and enables chemotaxis
J. Leukoc. Biol., July 1, 2005; 78(1): 248 - 258.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
K. Budzyn, P. D. Marley, and C. G. Sobey
Opposing Roles of Endothelial and Smooth Muscle Phosphatidylinositol 3-Kinase in Vasoconstriction: Effects of Rho-Kinase and Hypertension
J. Pharmacol. Exp. Ther., June 1, 2005; 313(3): 1248 - 1253.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
B. Teng, W. Qin, H. R. Ansari, and S. J. Mustafa
Involvement of p38-mitogen-activated protein kinase in adenosine receptor-mediated relaxation of coronary artery
Am J Physiol Heart Circ Physiol, June 1, 2005; 288(6): H2574 - H2580.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
C. R. Flynn, C. M. Brophy, E. J. Furnish, P. Komalavilas, D. Tessier, J. Thresher, and L. Joshi
Transduction of phosphorylated heat shock-related protein 20, HSP20, prevents vasospasm of human umbilical artery smooth muscle
J Appl Physiol, May 1, 2005; 98(5): 1836 - 1845.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
L. J. Rubin, L. Magliola, X. Feng, A. W. Jones, and C. C. Hale
Metabolic activation of AMP kinase in vascular smooth muscle
J Appl Physiol, January 1, 2005; 98(1): 296 - 306.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
B. Tolloczko, P. Turkewitsch, M. Al-Chalabi, and J. G. Martin
LY-294002 [2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] Affects Calcium Signaling in Airway Smooth Muscle Cells Independently of Phosphoinositide 3-Kinase Inhibition
J. Pharmacol. Exp. Ther., November 1, 2004; 311(2): 787 - 793.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
T. C. Jackson, Z. Mi, and E. K. Jackson
Modulation of Cyclic AMP Production by Signal Transduction Pathways in Preglomerular Microvessels and Microvascular Smooth Muscle Cells
J. Pharmacol. Exp. Ther., July 1, 2004; 310(1): 349 - 358.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
E. A. Wehrwein, C. A. Northcott, R. D. Loberg, and S. W. Watts
Rho/Rho Kinase and Phosphoinositide 3-Kinase Are Parallel Pathways in the Development of Spontaneous Arterial Tone in Deoxycorticosterone Acetate-Salt Hypertension
J. Pharmacol. Exp. Ther., June 1, 2004; 309(3): 1011 - 1019.
[Abstract] [Full Text] [PDF]


Home page
Mol. Biol. CellHome page
X. Shi-Wen, Y. Chen, C. P. Denton, M. Eastwood, E. A. Renzoni, G. Bou-Gharios, J. D. Pearson, M. Dashwood, R. M. du Bois, C. M. Black, et al.
Endothelin-1 Promotes Myofibroblast Induction through the ETA Receptor via a rac/Phosphoinositide 3-Kinase/Akt-dependent Pathway and Is Essential for the Enhanced Contractile Phenotype of Fibrotic Fibroblasts
Mol. Biol. Cell, June 1, 2004; 15(6): 2707 - 2719.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
C. A. Northcott, J. S. Hayflick, and S. W. Watts
PI3-Kinase Upregulation and Involvement in Spontaneous Tone in Arteries From DOCA-Salt Rats: Is p110{delta} the Culprit?
Hypertension, April 1, 2004; 43(4): 885 - 890.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
X. Su, E. M. Smolock, K. N. Marcel, and R. S. Moreland
Phosphatidylinositol 3-kinase modulates vascular smooth muscle contraction by calcium and myosin light chain phosphorylation-independent and -dependent pathways
Am J Physiol Heart Circ Physiol, February 1, 2004; 286(2): H657 - H666.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
L. Zhang, N. Yang, D. Katsaros, W. Huang, J.-W. Park, S. Fracchioli, C. Vezzani, I. A. Rigault de la Longrais, W. Yao, S. C. Rubin, et al.
The Oncogene Phosphatidylinositol 3'-Kinase Catalytic Subunit {alpha} Promotes Angiogenesis via Vascular Endothelial Growth Factor in Ovarian Carcinoma
Cancer Res., July 15, 2003; 63(14): 4225 - 4231.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
R. D. Loberg, C. A. Northcott, S. W. Watts, and F. C. Brosius III
PI3-Kinase-Induced Hyperreactivity in DOCA-Salt Hypertension Is Independent of GSK-3 Activity
Hypertension, April 1, 2003; 41(4): 898 - 902.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
C. A. Northcott, M. N. Poy, S. M. Najjar, and S. W. Watts
Phosphoinositide 3-Kinase Mediates Enhanced Spontaneous and Agonist-Induced Contraction in Aorta of Deoxycorticosterone Acetate-Salt Hypertensive Rats
Circ. Res., August 23, 2002; 91(4): 360 - 369.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (25)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Komalavilas, P.
Right arrow Articles by Brophy, C. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Komalavilas, P.
Right arrow Articles by Brophy, C. M.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online